As Covid-19 spreads, disruptions to clinical trial and drug development accelerate

As Covid-19 spreads, disruptions to clinical trial and drug development accelerate

Source: 
Stat
snippet: 

The disruption of clinical trials due to the novel coronavirus pandemic is becoming an almost daily ritual.

The scope of the clinical trial delays and suspension — like just about everything touched by this expanding crisis — is hard to quantify, but consider this snapshot: Biotech and pharma companies are currently running more than 120 Phase 3 clinical trials with top-line data readouts expected before the end of the year, according to search of a database maintained by BioMedTracker.